Breast Cancer Clinical Trial
Official title:
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Verified date | April 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Flight attendants may be at an increased risk of breast and other cancers due to work-place
exposures including cosmic radiation and circadian rhythm disruption form traveling across
multiple time zones. This cancer incidence study will determine whether female flight
attendants are at increased risk of breast and other cancers and whether the risk is
dose-related. The study will include a cohort of approximately 10,000 women who were employed
as flight attendants for one or more years.
Breast cancer cases will be identified from telephone interviews of living subjects and
next-of-kin of deceased subjects, as well as from death certificates. The interview will also
provide information about non-occupational risk factors for breast cancer such as parity.
Both internal and external comparisons will be made. The primary analysis will evaluate the
risk associated with occupational exposure within the cohort, controlling for
non-occupational risk factors by stratification or modeling. The secondary analysis will
compare the incidence of breast cancer in the cohort to that in the general population, with
adjustment for factors such as lower parity which might increase breast cancer risk in the
cohort independent of occupational exposure to cosmic radiation and circadian rhythm
disruption. The risk of other ionizing radiation-related cancers, such as leukemia, lung
cancer, and thyroid cancer, among flight attendants will also be evaluated. The results of
the study will apply to female flight crew and frequent fliers.
Status | Completed |
Enrollment | 6093 |
Est. completion date | April 9, 2020 |
Est. primary completion date | December 31, 2005 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 100 Years |
Eligibility |
- INCLUSION CRITERIA: Employed as a flight attendant for one or more years by Pan AM before Pan Am ceased operation in 1991. For flight attendants who transferred to Pan Am from National Airlines when Pan Am bought National Airlines in 1981, the time employed as a flight attendant at National Airlines will be counted towards the one year minimum. A U.S. citizen when they began working at Pan Am (or National Airlines, if the flight attendant transferred to Pan AM from National Airlines). Worked at least one day after January 1, 1953. |
Country | Name | City | State |
---|---|---|---|
United States | National Institute for Occupational Safety and Health (NIOSH) | Cincinnati | Ohio |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH/CDC) |
United States,
Grajewski B, Waters MA, Whelan EA, Bloom TF. Radiation dose estimation for epidemiologic studies of flight attendants. Am J Ind Med. 2002 Jan;41(1):27-37. — View Citation
Pinkerton LE, Waters MA, Hein MJ, Zivkovich Z, Schubauer-Berigan MK, Grajewski B. Cause-specific mortality among a cohort of U.S. flight attendants. Am J Ind Med. 2012 Jan;55(1):25-36. doi: 10.1002/ajim.21011. Epub 2011 Oct 10. — View Citation
Waters MA, Grajewski B, Pinkerton LE, Hein MJ, Zivkovich Z. Development of historical exposure estimates of cosmic radiation and circadian rhythm disruption for cohort studies of Pan Am flight attendants. Am J Ind Med. 2009 Oct;52(10):751-61. doi: 10.1002/ajim.20738. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Breast and other cancers | survival | Time of questionnaire, time of death |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |